WO2010082789A2 - Compositions anticancéreuses comprenant du cédrol nanoparticulaire - Google Patents
Compositions anticancéreuses comprenant du cédrol nanoparticulaire Download PDFInfo
- Publication number
- WO2010082789A2 WO2010082789A2 PCT/KR2010/000276 KR2010000276W WO2010082789A2 WO 2010082789 A2 WO2010082789 A2 WO 2010082789A2 KR 2010000276 W KR2010000276 W KR 2010000276W WO 2010082789 A2 WO2010082789 A2 WO 2010082789A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cedrol
- cancer
- acid
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229940026455 cedrol Drugs 0.000 title claims abstract description 60
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 title claims abstract description 60
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 title claims abstract description 60
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 title claims abstract description 59
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000001093 anti-cancer Effects 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 26
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 26
- 238000000527 sonication Methods 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 229920001222 biopolymer Polymers 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 33
- 229940079593 drug Drugs 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 26
- 229940068984 polyvinyl alcohol Drugs 0.000 description 25
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000005538 encapsulation Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000013268 sustained release Methods 0.000 description 8
- 239000012730 sustained-release form Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 240000005308 Juniperus chinensis Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- -1 poly(lactide) Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YGBZFOQXPOGACY-VWVSFFKRSA-N (1s,4ar,5s,8ar)-1,4a-dimethyl-6-methylidene-5-[(2e)-3-methylpenta-2,4-dienyl]-3,4,5,7,8,8a-hexahydro-2h-naphthalene-1-carboxylic acid Chemical compound [C@H]1([C@@](CCC2)(C)C(O)=O)[C@@]2(C)[C@@H](C\C=C(C=C)/C)C(=C)CC1 YGBZFOQXPOGACY-VWVSFFKRSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- NVEQFIOZRFFVFW-RGCMKSIDSA-N caryophyllene oxide Chemical compound C=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 NVEQFIOZRFFVFW-RGCMKSIDSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000008184 oral solid dosage form Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- YGBZFOQXPOGACY-UHFFFAOYSA-N ozic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C(CC=C(C=C)C)C(=C)CC2 YGBZFOQXPOGACY-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- IPEHJNRNYPOFII-AZUAARDMSA-N sugiol Chemical compound CC([C@@H]1CC2=O)(C)CCC[C@]1(C)C1=C2C=C(C(C)C)C(O)=C1 IPEHJNRNYPOFII-AZUAARDMSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- ISHVJVXYPLFKAL-UHFFFAOYSA-N (+)-8,11,13-abietatrien-7-one Natural products CC1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3C(=O)CC21 ISHVJVXYPLFKAL-UHFFFAOYSA-N 0.000 description 1
- DOYKMKZYLAAOGH-LECCCLRSSA-N (+)-Isocupressic acid Natural products O=C(O)[C@]1(C)[C@@H]2[C@@](C)([C@@H](CC/C(=C\CO)/C)C(=C)CC2)CCC1 DOYKMKZYLAAOGH-LECCCLRSSA-N 0.000 description 1
- QYCOHMYDSOZCQD-GWEOMKHGSA-N (1s,4ar,5s,8ar)-5-[(e)-4-carboxy-3-methylbut-3-enyl]-1,4a-dimethyl-6-methylidene-3,4,5,7,8,8a-hexahydro-2h-naphthalene-1-carboxylic acid Chemical compound [C@H]1([C@@](CCC2)(C)C(O)=O)[C@@]2(C)[C@@H](CCC(/C)=C/C(O)=O)C(=C)CC1 QYCOHMYDSOZCQD-GWEOMKHGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ODFCWXVQZAQDSO-CMKODMSKSA-N (2s,4as,10ar)-1,1,4a-trimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-2,6-diol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)C1=C2C=C(C(C)C)C(O)=C1 ODFCWXVQZAQDSO-CMKODMSKSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ISHVJVXYPLFKAL-AZUAARDMSA-N 7-dehydroabietanone Chemical compound CC1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3C(=O)C[C@H]21 ISHVJVXYPLFKAL-AZUAARDMSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- QYCOHMYDSOZCQD-UHFFFAOYSA-N Agathic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C(CCC(C)=CC(O)=O)C(=C)CC2 QYCOHMYDSOZCQD-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- IPEHJNRNYPOFII-UHFFFAOYSA-N DL-Sugrol Natural products O=C1CC2C(C)(C)CCCC2(C)C2=C1C=C(C(C)C)C(O)=C2 IPEHJNRNYPOFII-UHFFFAOYSA-N 0.000 description 1
- WPOUKVDSMRPXGT-UHFFFAOYSA-N Dehydroabietinol Natural products CC(C)c1ccc2C3CCCC(C)(CO)C3CCc2c1 WPOUKVDSMRPXGT-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LKSYOLUCMPBADN-UHFFFAOYSA-N Isoleptographiol Natural products C1C(C)(C)CC2C(O)(C)CCC2C2(C)CC21 LKSYOLUCMPBADN-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- CKZZREIPBTYJEQ-UHFFFAOYSA-N Totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(C)C=C2 CKZZREIPBTYJEQ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- DOYKMKZYLAAOGH-UHFFFAOYSA-N Viscidic acid A Natural products C1CCC(C(O)=O)(C)C2C1(C)C(CCC(C)=CCO)C(=C)CC2 DOYKMKZYLAAOGH-UHFFFAOYSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- XDVDHFJMCJWDPI-UHFFFAOYSA-N alpha-acorenol Natural products CC1CCC(C(C)(C)O)C11CC=C(C)CC1 XDVDHFJMCJWDPI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- SRSPZMSNYAVIMD-UHFFFAOYSA-N beta-cuparenol Natural products C1=CC(C)=CC=C1C1(C)C(C)(C)CC(O)C1 SRSPZMSNYAVIMD-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- RSYBQKUNBFFNDO-UHFFFAOYSA-N caryophyllene oxide Natural products CC1(C)CC2C(=C)CCC3OC3(C)CCC12C RSYBQKUNBFFNDO-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- WSKGRAGZAQRSED-SLFFLAALSA-N dehydroabietadienol Chemical compound OC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 WSKGRAGZAQRSED-SLFFLAALSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940108890 emend Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000002389 environmental scanning electron microscopy Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- QXNWVJOHUAQHLM-AZUAARDMSA-N ferruginol Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)C1=C2C=C(C(C)C)C(O)=C1 QXNWVJOHUAQHLM-AZUAARDMSA-N 0.000 description 1
- HOJWCCXHGGCJQV-YLJYHZDGSA-N ferruginol Natural products CC(C)c1ccc2c(CC[C@@H]3C(C)(C)CCC[C@]23C)c1O HOJWCCXHGGCJQV-YLJYHZDGSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- DOYKMKZYLAAOGH-DOEMEAPXSA-N isocupressic acid Chemical compound [C@H]1([C@@](CCC2)(C)C(O)=O)[C@@]2(C)[C@@H](CCC(/C)=C/CO)C(=C)CC1 DOYKMKZYLAAOGH-DOEMEAPXSA-N 0.000 description 1
- BOVFKJJRUSBLPS-UHFFFAOYSA-N isocupressic acid Natural products CC(=C/CO)CCCC1C(=C)CCC2C1(C)CCCC2(C)C(=O)O BOVFKJJRUSBLPS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- MGQMYSVCEMGOPL-WQTQMUQDSA-N methyl (1s,4ar,5s,8ar)-5-[(e)-5-acetyloxy-3-methylpent-3-enyl]-4a-methyl-6-methylidene-1,2,3,4,5,7,8,8a-octahydronaphthalene-1-carboxylate Chemical compound C[C@]1([C@H](C(=C)CC2)CC\C(C)=C\COC(C)=O)[C@H]2[C@@H](C(=O)OC)CCC1 MGQMYSVCEMGOPL-WQTQMUQDSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011146 organic particle Substances 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920000767 polyaniline Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- RIGGCOJUFQBLRZ-UHFFFAOYSA-N thujopsenol Natural products CC1(C)CCCC2(C)CC=C(CO)C3CC123 RIGGCOJUFQBLRZ-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- ZRVDANDJSTYELM-FXAWDEMLSA-N totarol Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)C1=C2C(C(C)C)=C(O)C=C1 ZRVDANDJSTYELM-FXAWDEMLSA-N 0.000 description 1
- 229940074347 totarol Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- YGBZFOQXPOGACY-LFGUQSLTSA-N trans-communic acid Natural products CC(=C/C[C@@H]1C(=C)CC[C@@H]2[C@]1(C)CCC[C@]2(C)C(=O)O)C=C YGBZFOQXPOGACY-LFGUQSLTSA-N 0.000 description 1
- ZRVDANDJSTYELM-UHFFFAOYSA-N trans-totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(O)C=C2 ZRVDANDJSTYELM-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- HSANNLXBHKRHSH-UHFFFAOYSA-N viscidic acid B Natural products C1CCC(C(O)=O)(C)C2C1(C)C(CCC(C)=CCOC(=O)C)C(=C)CC2 HSANNLXBHKRHSH-UHFFFAOYSA-N 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to a method for preparing cedrol or a pharmaceutically acceptable salt thereof in a nanoparticle form, and a composition for the treatment and prevention of cancer, comprising the nanoparticles prepared by the same.
- Nanobiotechnology initially got started with the manufacture of nano-scale structures and has become a growing field of interest worldwide. Most of the methods can be used in the preparation of drug particles as well as other various organic particles, and also for nano encapsulation (see, Zhiping Zhang and Si-Shen Feng, The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)tocopheryl polyethylene glycol succinate nanoparticles, Biomaterials, 27, 4025-4033. 2006).
- Cedrol as used herein belongs to this set of poorly soluble drugs.
- Juniperus chinensis an evergreen coniferous tree native to Korea, is widely distributed. It has the efficacies of relieving rheumatism, dispelling cold, extinguishing blood stasis, and detoxification, and has been used in traditional medicines for the treatment of cold, flu, joint pain caused by rheumatism, measles, induration, and the early stage of tumor. Recently, several chemical ingredients have been isolated from Juniperus chinensis, and their structures have been also clarified.
- norpimarane and norabietanes were isolated from the leaf of Juniperus chinensis, and many chemical ingredients ( ⁇ -cuparenol, ⁇ -acorenol, thujopsen-12-ol, isoleptographiol, caryophylleneoxide, 6,7-epoxycaryophyll-3-en-14-ol, cedrol, cedran-3a-ol, cedrane-3/3,12-diol, ferruginol, hinokiol, dehydroabietinol, abieta-8, 11,13-trien-7-one, sugiol, totarol, sandaracopimaric, trans -communic acid, cis -communic acid, agathic acid, isocupressic acid, acety lisocupressic acid, 15-hydroxylabd-8-en-19-oic acid, 15,16-bisnor-13-oxolabda
- cedrol or the pharmaceutically acceptable salt thereof exhibits excellent therapeutic and prophylactic effects on cancer.
- cedrol is a poorly soluble compound, it has been difficult to formulate it into oral solid dosage forms by the processes of granulation, mixing, and tabletting. Accordingly, the present inventors considered many methods for introducing cedrol into the human body. They found that a nanoparticle form of cedrol prepared by the present method is easily introduced into a human body and exhibits an excellent sustained release effect in the body, and thus can be effectively used for the treatment and prevention of cancer, thereby completing the present invention.
- Nano drug delivery systems are advantageous in that selective, topical treatment can be achieved. Therefore, much focus has been placed on nano drug delivery systems.
- the nanoparticle form (NM) of a drug or poorly soluble molecule could reduce side effects of the drug and maximize its efficacy.
- the composition prepared by the present invention is very useful for the treatment and prevention of cancer.
- FIG. 1 is a diagram showing the process of preparing the nanoparticles comprising the cedrol or pharmaceutically acceptable salt thereof of the present invention
- FIGs. 2 and 3 are diagrams showing the size of the cedrol nanoparticles prepared by the method of the present invention, depending on PVA concentration and sonication time;
- FIGs. 4 to 9 are diagrams showing FE-SEM of the cedrol nanoparticles prepared by the method of the present invention, depending on PVA concentration and sonication time;
- FIG. 10 is the result of DSC thermogram showing physical properties of the cedrol nanoparticles prepared by the method of the present invention.
- FIG. 11 is a graph showing the cedrol release of the cedrol nanoparticles prepared by the method of the present invention, namely, the cedrol release of NM depending on PVA concentrations and time;
- FIGs. 12 to 16 are the results showing cytotoxicity depending on PVA concentrations and sonication time, when HT29 cells were treated with the cedrol nanoparticles prepared by the method of the present invention.
- FIG. 17 is the result of Western blot showing inhibition of MCM protein expression, when HT29 cells were treated with the cedrol nanoparticles prepared by the method of the present invention.
- FIG. 18 is a graph showing changes in body weight, when cancer animal models were treated with the cedrol nanoparticles prepared by the method of the present invention.
- FIG. 19 is a graph showing the tumor size over time, when cancer animal models were treated with the cedrol nanoparticles prepared by the method of the present invention.
- FIG. 20 is a graph showing the weight of tumor, resected from cancer animal models that were treated with the cedrol nanoparticles prepared by the method of the present invention.
- FIG. 21 is a diagram showing the reduced volume of malignant tissue, when cancer animal models were treated with the cedrol nanoparticles prepared by the method of the present invention.
- the present invention relates to a method for preparing cedrol or a pharmaceutically acceptable salt thereof in a nanoparticle form, comprising the steps of (a) dissolving the cedrol or the pharmaceutically acceptable salt thereof in an organic solvent, mixing the solution with an amphiphilic biopolymer and then mixing it with a surfactant at a concentration of 3 to 7%; (b) sonicating the mixture of (a) to form an emulsion; and (c) centrifuging and washing the emulsion of (b) 4 to 6 times and then drying it.
- cedrol or pharmaceutically acceptable salt thereof according to the present invention is described in Korean Patent No. 673574, and the disclosure is incorporated herein in its entirety, as long as it is within the scope of this invention.
- the cedrol of the present invention refers to a compound that induces apoptosis of cancer cells and has an inhibitory effect on cancer cell growth. More particularly, the cedrol of the present invention induces cell death of cancer cells by apoptosis through nuclear morphological change, release of mitochondrial cytochrome c, activation of caspase-8, caspase-9, and caspase-3, and cleavage of poly (ADP-ribose) polymerase, and has an inhibitory effect on the expression of a replication initiation factor, MCM protein.
- MCM protein replication initiation factor
- cedrol can be prepared by chemical synthesis methods well-known to those in the art, and preferably obtained by isolation from Juniperus chinensis, which is an evergreen coniferous tree belonging to the family Cupressaceae.
- Cedrol as used herein embraces a pharmaceutically acceptable salt thereof, optionally.
- the pharmaceutically acceptable salt of the cedrol of the present invention comprise all the acidic or basic salts which may be present in the compound of the present invention, as long as particular mention is not made.
- the pharmaceutically acceptable salt includes sodium salt, calcium salt, and potassium salt of hydroxy group
- other pharmaceutically acceptable salts of the amino group includes hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate).
- the salts can be produced by a preparation method or preparation process thereof known in the related art.
- acid addition salts prepared with free acids are preferred.
- the acid addition salts are prepared by the conventional method, for example, a method comprising the steps of dissolving a compound in an excessive amount of acid aqueous solution, and precipitating the salt using water-miscible organic solvents such as methanol, ethanol, acetone or acetonitrile.
- Acid or alcohol e.g., glycol monomethylether
- the mixture is dried by evaporation or the precipitated salt can be suction-filtered.
- organic acids and inorganic acids may be used.
- the inorganic acids include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, and tartaric acid
- examples of the organic acids include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, and hydroiodic acid.
- the pharmaceutically acceptable metal salt form may be prepared by using a base.
- the alkali metal or alkali-earth metal salt thereof can be prepared by a conventional method, for example, after dissolving the compound in an excess amount of alkali metal hydroxide or alkali-earth metal hydroxide solution, the insoluble salts are filtered and remaining filtrate is subjected to evaporation and drying to obtain the metal salt thereof.
- sodium, potassium or calcium salt are pharmaceutically suitable and the corresponding silver salt can be prepared by reacting alkali metal salt or alkali-earth metal salt with suitable silver salt (e.g., silver nitrate).
- the first step is a step of dissolving the cedrol or the pharmaceutically acceptable salt thereof in an organic solvent, and mixing the solution with an amphiphilic biopolymer to mix it with a surfactant at a concentration of 3 to 7%.
- Cedrol is a poorly soluble compound, which has the property of being poorly soluble in water. Because of this property, there have been many difficulties in the preparation of a therapeutic or prophylactic drug for cancer comprising cedrol. Therefore, in order to solve the problem, cedrol is first dissolved in an organic solvent in the present invention. Any organic solvent may be used, and preferably methylene chloride, acetone, dichloromethane, dimethylformamide, dimethylsulfoxide, acetonitrile, tetrahydrofuran, or methanol. If necessary, the mixtures thereof may be used. Further, if necessary, they may be mixed with a small amount of water.
- the cedrol or pharmaceutically acceptable salt thereof dissolved in the organic solvent is mixed with an amphiphilic biopolymer.
- the amphiphilic biopolymer in any organic solvent may be used, preferably poly(lactic acid) or poly(lactic acid-co-glycolic acid).
- the cedrol or pharmaceutically acceptable salt thereof is preferably mixed with the amphiphilic biopolymer in a ratio of 1: 10, and more preferably in a ratio of 1: 5.
- a surfactant is dissolved in the solution at a concentration of 3 to 7%.
- the surfactant is dissolved in the solution at a concentration of 4 to 6%. If the concentration of the surfactant is more than 7%, there are disadvantages that the size of the final nanoparticle becomes larger, encapsulation efficiency becomes low, and sustained release of cedrol or pharmaceutically acceptable salt thereof increases. Therefore, when the concentration of the surfactant is within the proper range from 3 to 7%, preferably 4 to 6%, such disadvantages can be overcome. If the concentration of the surfactant is less than 0.5%, it may cause problems in the formation of nanoparticles.
- any surfactant may be used, preferably polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acid or derivatives thereof, cremophor or Tweens.
- the second step is a step of forming an emulsion by homogenization of the mixture.
- the homogenization may be performed by any known method in the art, preferably by sonication.
- the sonication time can be readily determined by those skilled in the art, depending on the sonication method and formed emulsion. As one specific example thereof, the sonication time is 3 min to 12 min, preferably 4 min to 10 min. If the sonication time is more than 12 min, there is a problem in that the prepared nanoparticles display cytotoxic effects. If the sonication time is less than 3 min, there is a problem in that the emulsion is not sufficiently formed.
- the third step is a step of centrifuging and washing the emulsion 4 to 6 times and then drying it.
- the centrifugation can be performed to fully separate the emulsion layer, and at the speed and for the time known to those skilled in the art.
- the washing is a process for removing impurities that may be included in the prepared nanoparticles.
- the centrifugation and washing are performed for the preparation of pure nanoparticles, and they can be performed 4 to 6 times, and preferably 4 to 5 times.
- the drying step is performed to obtain nanoparticle powder.
- the drying step is not essential, but can be selectively performed according to the final formulation of the prepared nanoparticles.
- the drying step is to prepare a particle form by removing any water or other compounds that are used during the process.
- the drying step may be performed by the drying methods known in the art, including freeze-drying, spray granulation, and spray drying, preferably freeze-drying. These drying methods are well known in the art.
- the nanoparticles of the cedrol or pharmaceutically acceptable salt thereof that are prepared by the method have a size of 100 to 500 nm, preferably 200 to 500 nm, and more preferably 200 to 400 nm.
- the nanoparticle forms of the cedrol or pharmaceutically acceptable salt thereof that are prepared by the method have the advantages of excellent encapsulation efficiency and sustained release effect of the compounds, as compared to the native form of the cedrol or pharmaceutically acceptable salt thereof.
- the nanoparticle forms also have an inhibitory effect on overexpression of MCM protein, equal to that of the native form.
- the present invention provides a pharmaceutical composition for the treatment and prevention of cancer, comprising the nanoparticles of cedrol or a pharmaceutically acceptable salt thereof that are prepared by the method.
- the cancer disease includes general cancer diseases, including stomach cancer, colon cancer, breast cancer, lung cancer, non-small cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or ocular melanoma, uterine cancer, ovarian cancer, large intestine cancer, small intestine cancer, rectal cancer, anal cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin s disease, esophageal cancer, small intestine cancer, lymphoma, bladder cancer, gallbladder cancer, endocrine adenocarcinoma, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostatic cancer, chronic or acute leukemia, lymphocyte lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvic carcinoma, central nervous system tumor, primary central nervous system lymphoma, spinal tumor, brain stem glioma, and pitu
- the composition for the treatment and prevention of cancer of the present invention comprises the nanoparticle in an amount of 0.1 to 50% by weight, based on the total weight of the composition.
- the nanoparticle contains a smaller amount of the cedrol compound, it has excellent sustained release effect to maintain its efficacy for a long period of time.
- the composition of the present invention may comprise any pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier used in the composition of the present invention may be at least one selected from an excipient, a disintegrating agent, a binder, and a lubricant.
- an excipient such as microcrystalline cellulose, lactose, low-substituted hydroxycellulose
- a disintegrating agent such as sodium starch glycolate, anhydrous calcium hydrogen phosphate
- a binder such as polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, or hydroxypropylcellulose
- a glidant such as magnesium stearate, silicon dioxide, or talc.
- an additive imparting gloss to a tablet such as anhydrous dibasic calcium phosphate
- a tablet may also be coated with a water-insoluble material to prevent the infiltration of moisture in air into the tablet.
- the coating material should have a compact molecular structure and may not be easily dissolved in an aqueous solution.
- the coating material may be a polymer material such as a methacrylic acid copolymer, hydroxypropylmethylcellulose phthalate, celluloseacetate phthalate, hydroxypropylmethylcellulose acetatesuccinate, and polyvinylalcohol. These polymer materials may be used alone or in combination.
- a coating layer coated on a tablet may include an additive for a coating material commonly known in the art, e.g., a plasticizer, a preservative, a pigment, or a light shielding agent.
- composition of the present invention may be presented in the form of solutions such as sterile aqueous solution, or injectables.
- solutions such as sterile aqueous solution, or injectables.
- Such solution contains, if necessary, from 10 to 40% of propylene glycol and sodium chloride sufficient to avoid hemolysis (e.g. about 1%).
- the composition of the present invention may be formulated into pharmaceutical preparations common in the pharmaceutical field.
- the formulations include injectable formulations, tablets, capsules, powders, granules, suspensions, emulsions, syrups, emulsions in water, plasters, ointments, aerosols, oils, gels, spirits, tinctures, baths, liniments, lotions, patches, pads and creams, preferably injectable formulations, tablets, capsules, powders, aerosols, or patches, and more preferably tablets or capsules for oral administration, aerosols inhalable via the respiratory tract, or patches applicable to a desired area of the skin, and injectable formulations for parenteral administration.
- a propellant for spraying a water-dispersed concentrate or wetting powder may be used in combination with an additive.
- a permeation stimulator may be used to increase the permeation of compounds through the skin.
- the present invention relates to a method for treating and/or preventing cancer by administration of the pharmaceutical composition into an individual.
- the term "individual” refers to any mammal in need of treatment for cancer, including human and non-human primates, domestic animals and livestock, pet or sports animals, for example, dogs, horses, cats, sheep, pigs, and cows.
- the individual in need of treatment of cancer is preferably human.
- composition of the present invention may be administered via various routes such as oral, parenteral, topical, rectal, and intranasal routes.
- Parenteral administrations include indirect injections to generate a systemic effect or direct injections to the afflicted area. Examples of parenteral administrations are subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular injections or infusions techniques.
- Topical administrations include the treatment of infectious areas or organs readily accessible by local application, for example, eyes, ears including external and middle ear infections, vaginal, open and sutured or closed wounds and skin. It also includes transdermal delivery to generate a systemic effect.
- Intranasal administration includes nasal aerosol or inhalation applications
- composition of the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount refers to an amount sufficient to exert the effects of the composition, and further an amount not to cause an adverse reaction, or serious or excessive immunity response.
- An exact effective dose level may be readily determined by those skilled in the art, depending on the factors well known in the medical field such as the patient s age, weight, health condition, and sex, drug sensitivity, the route of administration, and administration method.
- the composition of the present invention can be administered once to several times. For example, according to the severity of the disorder, it may be administered once daily or every 4 to 6 hours. To treat an acute case, the composition of the present invention is preferably administered every 4 to 6 hours. For the purpose of prevention (or maintenance), it is preferably administered once or twice daily.
- the composition for the treatment and/or prevention of cancer according to the present invention may be administered two or more times daily, depending on the characteristics of disease.
- Methylene chloride (Dichloromethane, DCM, analytical grade) was purchased from Merck (Germany), and acetonitrile (HPLC grade) was purchased from Malinckrodt Baker, Inc.
- cedrol nanoparticles (Nanomedicin, NM), poly(DL-lactic-co-glycolic acid) (PLGA) was used as an amphiphilic biopolymer, and polyvinyl alcohol (PVA) was used as a surfactant.
- PLGA poly(DL-lactic-co-glycolic acid)
- PVA polyvinyl alcohol
- the procedures are as follows. 40 mg of cedrol was fully dissolved in 16 ml of methylene chloride (DCM), and 200 mg of PLGA was mixed therewith. 100 ml of PVA solution was added to the mixed solution at the total concentrations of 0.5%, 5% and 10%, and sonication (60 W) was performed for 5 or 10 min to form an emulsion.
- the formed emulsion was transferred to a 50 ml centrifuge tube, and centrifuged at 12,000 rpm for 15 min. The resultant was washed with 10 ml of triple deionized water, and then centrifuged at 12,000 rpm for 15 min. This procedure was repeated five times, and PPT was suspended in 10 ml of distilled water, and frozen at -80°C, and freeze-dried for 48 hours to prepare NM particles. The procedures are shown in FIG. 1.
- the mean diameter of NM was 50 to 800nm, and poly-dispersity was 0.243 to 0.373.
- the size varied depending on PVA concentration and sonication time. As the PVA concentration increased, the size increased. However, as the sonication time increased, the size decreased.
- NP1 and NP3 showed no significant difference in their size (200 to 500 nm), but NP5 showed a great size difference of 600 to 900 nm.
- NP4 had the smallest particle size, and subsequently, NP2 was the second smallest, and well-dispersed. There was no significant difference between NP5 and NP6 of FIG. 2.
- the surface morphology of NM was measured by field emission scanning electron microscopy (FE-SEM, Quanta 200 FEG ESEM, Czech). The results are shown in FIGs. 4 to 9.
- the measurement was performed under a nitrogen environment, and about 5 mg of blend sample was used to maintain the constant mass of polymeric components in the blend.
- FIG. 10 is the results showing the physical properties of NM, in which each represents gelation temperature, melting temperature, and crystallization temperature, and showing crystallization during the first and second heating cycles, in which Tg, Tm, and Tc of the first cedrol(CR) were near 55°C, 90°C, and 50°C, respectively.
- the biodegradable polymer, PLGA was melted at 57°C, and NM had both of the melting peaks appeared in CR and PLGA, indicating that NM is a nanoparticle to form a micelle.
- Encapsulation efficiency of NM was analyzed by HPLC (Waters alliance 2690). Reverse phase Inertsil XTrra TM RP18 (4.6' 150mm i.d., pore size 5 ⁇ m, Waters, Tokyo, Japan) was used as a column, and acetonitrile-water (60:40) was used as a developing solvent for elution. The measurement was performed at 195 nm. 6 mg of NM 3 prepared in Example 1 was dissolved in 1 ml of DCM. After evaporating DCM completely, it was dissolved in 1.5 ml of acetonitrile-water (60:40), and the amount of eluted drug was measured by HPLC. The encapsulation efficiency was calculated by the following Equation 1.
- Encapsulation efficiency (EE) was in the wide range from 48 to 90%, and within 10% in the correction experiment.
- the correction values were shown in Table 1.
- Table 1 As shown in Table 1, when the concentration of PVA was high, the encapsulation efficiency was considerably low. As the concentration of PVA decreased, the encapsulation efficiency increased. Therefore, it can be seen that when the concentration of PVA is within 5%, the encapsulation efficiency has the optimal value.
- Example 1 8 mg of NM prepared in Example 1 was suspended in 10 ml of PBS (pH 7.4). While shaking the solution in a 37°C shaking water bath for 120 min at 100 rpm, the amount of drug release was measured by HPLC at suitable time intervals to evaluate sustained-release efficiency of the drug. The results are shown in FIG. 11.
- Non PVA (emulsifier)-treated group had 50% of drug release, and the cedrol release increased at a low concentration of PVA. As the PVA concentration increased, the cedrol release remarkably decreased. Taken together, the sustained release of drug increased at the PVA concentration within 5% and higher sonication time, namely at small size and high dispersity.
- MTT 3-(4,-dimethylthiazol-2-yl)-2,5- diphenyltetrazoliumbromide
- cell viability of the NM (15 to 30 ⁇ g/ml)-treated HT29 cells decreased in a concentration-dependent manner.
- the highest cytotoxic activity against HT-29 cells was observed at 5% PVA and sonication time of 10 min.
- Example 4 MCM protein expression of NM-treated HT29 cell
- MCM protein is an essential eukaryotic DNA replication factor having a helicase activity, and functions to control DNA replication by phosphorylation and dephosphorylation in normal cells.
- MCM protein expression is not tightly regulated, cells undergo unlimited proliferation and transformation into cancer cells. It was reported that the MCM protein expression is much higher in cancer cells than normal cells(Ishimi Y, et al., Eur J Biochem, 270(6), 1089-101, 2003).
- NM prepared in Example 1 was dissolved in PBS, which was applied to HT29 cells at various concentrations, and then the sample-treated cancer cells were suspended in a CSK buffer (10 mM Pipes, pH 6.8, 100 mM NaCl, 1 mM MgCl 2 , 1 mM EGTA ,1 mM dithiothreitol, 1 mM phenylmethanesulfonyl fluoride) supplemented with 0.1% Triton X-100, 1 mM ATP and Protease inhibitor (Pharminogen A).
- CSK buffer 10 mM Pipes, pH 6.8, 100 mM NaCl, 1 mM MgCl 2 , 1 mM EGTA ,1 mM dithiothreitol, 1 mM phenylmethanesulfonyl fluoride
- the cell suspension was sonicated to obtain MCM-2, -3, -5, -6, and -7, PCNA, and actin proteins.
- the sonicated cells were centrifuged at 20,000 x g for 30 min to obtain the supernatant, and the protein concentration of the supernatant was determined using a BCA protein assay kit (Bio-Rad). An equal amount of protein (40) was used, and actin was used as a control group to perform SDS-PAGE. 15% and 10% separation gels were used for actin and MCM-2, -3, -5, -6, and -7, respectively.
- the proteins in the gels were transferred to a PVDF membrane, and blocking was performed using a blocking solution (Blockace TM , Dai-Nippon) at room temperature for 1 hr.
- the PVDF membrane was reacted with primary antibodies at 37°C for 1 hr, and washed with TBS (50 mM Tris/HCl, pH 7.5, 0.15 M NaCl) containing 0.1% Triton X-100.
- the PVDF membrane was reacted with peroxidase-conjugated secondary antibodies (Pierce) at 37 C for 1 hr, and detected by chemiluminescence system (SuperSignal West Femto Maximum sensitivity Substrate, Pierce). The reactivity was quantified using a Fluorchem TM 5500 (Alpha Innotech). The results are shown in FIG. 17.
- MCM 2 to 7 proteins As shown in FIG. 17, reduced expression of MCM 2 to 7 proteins was observed in the NM-treated HT29 cells, indicating inhibition of the overexpression of MCM protein, which is an essential DNA replication factor having a helicase activity in cancer cells.
- Example 5 Inhibitory effect of NM on malignant tissue
- mice 4 to 5 week-old male C57bl/6 mice (weight of 15-20 g) were divided into four groups of 6 animals each. All mice were acclimated for 1 week, and subcultured B16/F10 melanoma cells of 5 x 10 6 cells/ml were injected into the right armpit region to induce cancer.
- NM suspended in PBS was administered by intravenous, intraperitoneal, and oral injection. After 18 days, the mice were sacrificed to resect the malignant tissues.
- Table 2 and FIG. 18 show changes in body weight of cancer mouse model after NM treatment.
- mice treated with intraperitoneal injection were 2.24 g, whereas that of the control group was 5.1 g. That is, NM reduced the tumor weight by 50% or more.
- the tumor weights of the mice treated with intravenous and oral injection were 3.61 g and 3.76 g, showing that the tumor weight reduced to 30%, compared to the control group (see Table 3 and FIGs. 19 to 21).
- Tumor primary site (a x b)/2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une méthode de préparation de cédrol ou de l'un de ses sels pharmacocompatible sous forme de nanoparticules, et sur une composition de traitement et de prévention du cancer comprenant les nanoparticules ainsi préparées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090003868A KR20100084399A (ko) | 2009-01-16 | 2009-01-16 | 나노입자 형태로 세드롤을 포함하는 항암 조성물 |
KR10-2009-0003868 | 2009-01-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010082789A2 true WO2010082789A2 (fr) | 2010-07-22 |
WO2010082789A3 WO2010082789A3 (fr) | 2010-11-18 |
Family
ID=42340221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/000276 WO2010082789A2 (fr) | 2009-01-16 | 2010-01-15 | Compositions anticancéreuses comprenant du cédrol nanoparticulaire |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20100084399A (fr) |
WO (1) | WO2010082789A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870161B (zh) * | 2021-02-02 | 2023-03-21 | 贵州大学 | 一种雪松醇纳米乳及其优化制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951836B2 (en) * | 2000-01-05 | 2005-10-04 | Basf Aktiengesellschaft | Microcapsule preparations and detergents and cleaning agents containing microcapsules |
KR100673574B1 (ko) * | 2005-12-19 | 2007-01-24 | 학교법인 동의학원 | 향나무로부터 분리된 세드롤을 함유하는 암 예방 및치료용 조성물 |
WO2008054042A1 (fr) * | 2006-11-01 | 2008-05-08 | Jae Woon Nah | Nanoparticules biodégradables de poly(dl-lactide-co-glycolide) encapsulant le chlorhydrate de ciprofloxacine ayant une propriété de libération prolongée et son procédé de fabrication |
US20080213198A1 (en) * | 2004-04-26 | 2008-09-04 | Sederma Sas | Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer |
-
2009
- 2009-01-16 KR KR1020090003868A patent/KR20100084399A/ko not_active IP Right Cessation
-
2010
- 2010-01-15 WO PCT/KR2010/000276 patent/WO2010082789A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951836B2 (en) * | 2000-01-05 | 2005-10-04 | Basf Aktiengesellschaft | Microcapsule preparations and detergents and cleaning agents containing microcapsules |
US20080213198A1 (en) * | 2004-04-26 | 2008-09-04 | Sederma Sas | Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer |
KR100673574B1 (ko) * | 2005-12-19 | 2007-01-24 | 학교법인 동의학원 | 향나무로부터 분리된 세드롤을 함유하는 암 예방 및치료용 조성물 |
WO2008054042A1 (fr) * | 2006-11-01 | 2008-05-08 | Jae Woon Nah | Nanoparticules biodégradables de poly(dl-lactide-co-glycolide) encapsulant le chlorhydrate de ciprofloxacine ayant une propriété de libération prolongée et son procédé de fabrication |
Also Published As
Publication number | Publication date |
---|---|
WO2010082789A3 (fr) | 2010-11-18 |
KR20100084399A (ko) | 2010-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5128948B2 (ja) | 癌の治療のための新規な薬剤組成物 | |
JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
García-Rodriguez et al. | Changed crystallinity of mebendazole solid dispersion: improved anthelmintic activity | |
AU2015242738B2 (en) | Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same | |
JP6453482B2 (ja) | 固体分散体 | |
KR100930329B1 (ko) | 6-머캅토퓨린의 개선된 제제 | |
KR20030010724A (ko) | 방출 pH 범위 및/또는 속도 제어 조성물 | |
CN104507902A (zh) | 蒽醌类似物以及其制备和使用方法 | |
US10105365B2 (en) | Solid antiviral dosage forms | |
KR20080043852A (ko) | 신규 투여 제형 | |
KR20140014264A (ko) | 질내 투여용 속용성 정제 조성물 | |
CN113925833A (zh) | 包含酪氨酸蛋白激酶抑制剂的剂型组合物 | |
KR20060057514A (ko) | 생체이용율을 향상시킨 경구용 제제 | |
EP2854773B1 (fr) | Composition pharmaceutique d'entecavir, et procédé de fabrication | |
TW201511780A (zh) | 抗病毒化合物之固體分散調合物 | |
EA027641B1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
KR20210128939A (ko) | 경구 생체 이용률이 증가된 니클로사마이드 함유 고체분산체 및 이의 제조방법 | |
WO2010082789A2 (fr) | Compositions anticancéreuses comprenant du cédrol nanoparticulaire | |
JP7536098B2 (ja) | ウチデロンの経口固形製剤 | |
JP2018516942A (ja) | 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法 | |
KR20200014076A (ko) | 용출률 및 경구 흡수율이 개선된 셀레콕시브 고체 분산체 및 이의 제조방법 | |
JPH10324644A (ja) | ウレアーゼ阻害物質含有医薬組成物 | |
TW202019416A (zh) | 乙內醯脲衍生物的固體分散體 | |
TW202408525A (zh) | 包含帽依賴性核酸內切酶抑制劑的藥物組合物 | |
KR20110028178A (ko) | 실데나필-벤토나이트-aea 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10731404 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10731404 Country of ref document: EP Kind code of ref document: A2 |